anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Fibromyalgia patients vary in clinical phenotype and treatment can be challenging. The pathophysiology of fibromyalgia is incompletely understood but appears to involve metabolic changes at rest or in response to stress. We enrolled 54 fibromyalgia patients and 31 healthy controls to this prospective study. Symptoms were assessed using the Fibromyalgia Impact Questionnaire (FIQ) and blood samples were collected for metabolomics analysis at baseline and after an oral glucose tolerance test and a cardiopulmonary exercise test. We identified key symptoms of fibromyalgia and related them to changes in metabolic pathways with supervised and unsupervised machine learning methods. Algorithms trained with the FIQ information assigned the fibromyalgia diagnosis in new data with balanced accuracy of 88% while fatigue alone already provided the diagnosis with 86% accuracy. Supervised analyses reduced the metabolomic information from 77 to 13 key markers. With these metabolites, fibromyalgia could be identified in new cases with 79% accuracy. In addition, 5-hydroxyindole-3-acetic acid and glutamine levels correlated with the severity of fatigue. Patients differed from controls at baseline in tyrosine and purine pathways, and in the pyrimidine pathway after the stress challenges. Several key markers are involved in glutaminergic neurotransmission. This data-driven analysis highlights fatigue as a key symptom of fibromyalgia. Fibromyalgia is associated with metabolic changes which also reflect the degree of fatigue. Responses to metabolic and physical stresses result in a metabolic pattern that allows discrimination of fibromyalgia patients from controls and narrows the focus on key pathophysiological processes in fibromyalgia as treatment targets.
PROBLEM TO BE SOLVED: To use a specific compound stable to temperatures and having low volatility, extremely low migrating properties and antimicrobial activity for an antimicrobial finish, etc. of a polymeric compound exposed to an environment contaminated with microorganisms. SOLUTION: This compound represented by formula I or II [R1 and R2 are each H, a (substituted)1-10C alkyl, a (substituted)1-10C acyl, a (substituted)6-10C aryl or a (substituted)6-10C arylcarbonyl] is used as an antimicrobial agent. The compound represented by formula I is obtained by a method, etc. for reacting, e.g.  acetic anhydride with an acetic acid in which the carbon atom at the α-position is substituted with R1 or R2, reacting the resultant ketone represented by formula III (R4 is R1 or R2) with hydroxylamine hydrochloride, providing an oxime represented by formula IV, then reacting the prepared oxime with tosyl chloride in an aromatic solvent, affording a tosylate dissolving the resultant tosylate in an ethereal solvent, adding the formed solution into a cooled solution of metallic potassium in a dried alcohol, producing an aminoketone represented by formula V and reacting the produced aminoketone with thionyl chloride.
The Mindful Parenting program as developed by Bögels and Restifo (2013), is selected as one of the parenting intervention programs in this study. It is an 8-week program that trains parents in mindfulness and support them to apply mindfulness in parenting context.
Patients will receive 3 cycles of induction chemotherapy with gemcitabine and cisplatin and concurrent cisplatin-radiation plus Sintilimab, and then receive 11 cycles of Sintilimab after intensity-modulated radiotherapy (IMRT). All patients will receive IMRT. Sintilimab will begin on day 1 of induction chemotherapy and continue every 3 weeks for 17 cycles.
The present invention relates to a pharmaceutical composition for preventing or treating Fabri disease. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating Fabri disease containing a clathrin inhibitor, and a Quasi-drug composition, a health functional food composition, a feed or feed additive, or potable water or potable water additive for preventing or treating Fabri disease containing a clathrin inhibitor, and a method for preventing or treating Fabri disease using the composition. In addition, the present invention relates to a composition for diagnosing Fabri disease containing an agent for measuring clathrin levels, and a method for measuring and detecting clathrin expression levels to diagnose Fabri disease. The clathrin according to the present invention is abnormally expressed in high levels when Fabri disease is contracted and is thus used to diagnose, prevent and treat Fabri disease. Thus, the composition containing the clathrin inhibitor as an active ingredient of the present invention suppresses the expression of clathrin and effectively prevents, alleviates or treats Fabri disease when being injected into a subject. The composition for diagnosing Fabri disease containing an agent for measuring clathrin levels according to another aspect of the present invention is effective in diagnosing contraction or contraction possibility of Fabri disease.
Primary ovarian sarcoma is a rare malignancy, with primary ovarian leiomyosarcoma being even rarer because of the lack of smooth muscle in the ovaries. We herein report a case of primary ovarian leiomyosarcoma in a woman in her late 50s who presented with a 6-month history of abdominal pain. Imaging revealed a pelvic mass. The patient underwent surgery and was diagnosed with ovarian leiomyosarcoma. One month postoperatively, she began gemcitabine and docetaxel chemotherapy and continued this treatment for 6 months. Eight months postoperatively, however, recurrence was detected in the pelvic cavity. This case is reported with the aim of raising awareness about this rare disease.
Systematic detection of risky nutrition behaviors after sports surgery may better promote healing for return-to-sport. The purpose of this study was to assess nutritional behavior differences between patients following anterior cruciate ligament reconstruction (ACLR) and following other lower-extremity orthopedic surgeries. One pediatric sports medicine center was reviewed for a custom Sports Nutrition Assessment for Consultation, which investigates nutrition-related risk factors for youth athletes at their first post-operative visit. Patients reported "Yes" or "No" to eight questions, after which they were offered a nutrition consultation for any response indicating risk. A total of 243 post-ACLR and 242 non-ACLR patients were reviewed. The post-ACLR patients more often reported a change in appetite (p = 0.021), recent weight changes (p = 0.011), a desire to better understand nutrition (p = 0.004), and recommendations to change their body composition (p = 0.032). More post-ACLR patients were identified for a nutrition consultation (p = 0.002), though an equal percentage accepted the consultation between groups. Age and sex were not determined to be significant confounders after matched sub-analysis. The post-ACLR patients more often reported nutrition risks, specifically weight-related issues, regardless of age or sex. Sports surgeons should regularly inquire about nutrition-related concerns with patients and refer to sports dietitians for recovery nutrition support as needed, particularly after ACLR.
OBJECTIVES: We aimed to modify the Briganti 2019 nomogram and to test whether it is valid for patients who were diagnosed with prostate cancer through in-bore prostate biopsies.
METHODS: Data for 204 patients with positive multiparametric prostate MRI and prostate cancer identified either by mpMRI-cognitive/software fusion or in-bore biopsy and who underwent robot-assisted radical prostatectomy and extended pelvic lymph node dissection between 2012 and 2023 were retrospectively analyzed. The Briganti 2019 nomogram was applied to the mpMRI-cognitive/software fusion biopsy group (142 patients) in the original form, and then, two modifications were tested for the targeted component. Original and modified scores were compared. These modifications were adapted for the in-bore biopsy group (62 patients). The final histopathologic stage was regarded as the gold standard.
RESULTS: Nodal metastases were identified in 18/142 (12.6%) of mpMRI-cognitive/software fusion biopsy patients and 8/62 (12.9%) of the in-bore biopsy patients. In the mpMRI-cognitive/software fusion biopsy group, tumor size/core size (%) of targeted biopsy cores and positive core percentage on systematic biopsy were significant parameters for lymph node metastasis based on univariate logistic regression analyses (p < 0.05). With the modifications of these parameters for the in-bore biopsy group, V1 modification of the Briganti 2019 nomogram provided 100% sensitivity and 31.5% specificity (AUC:0.627), while V2 modification provided 75% sensitivity and 46.3% specificity (AUC:0.645).
CONCLUSIONS: Briganti 2019 nomogram may be modified by utilizing tumor size/core size (%) for targeted biopsy cores instead of positive core percentage on systematic biopsy or by not taking both parameters into consideration to detect node metastasis risk of patients diagnosed with in-bore biopsies.
Clinicians asked to participate in a 1:1 interview and a separate focus group at roughly the same time. Prior to the first structured interview with our study team, you will participate in a 1-hour training and familiarization session with the SOAR system using synthetic or training data.
Participants in this group performed a stretching protocol using contract-relax proprioceptive neuromuscular facilitation (crPNF). The participants are placed in a long sitting position with maximum knee extension possible until a moderate-strong stretch sensation is felt, without pain. The stretch lasts for 20 seconds, followed by a maximal voluntary isometric contraction of the hamstrings for 5 seconds. Three stretch-contraction cycles are completed. One researcher maintains the stretch position, while a second researcher controls the stretching and contraction times.
The invention discloses a polypeptide capable of serving as a type 5 phosphodiesterase inhibitor and application thereof. The polypeptide is tripeptide, and the amino acid sequence is Phe-Asp-His or Tyr-Asp-His. According to the structure and function relation of the prior PDE5 chemical inhibitor, the two active polypeptides of the invention are finally obtained through polypeptide design, polypeptide synthesis and in vitro activity measurement. When the mass concentration of the active ingredients is 5.56mg/mL, the inhibition rate of Phe-Asp-His to PDE5 reaches 91.21%, and the inhibition rate of Tyr-Asp-His to PDE5 reaches 89.80%. The polypeptide is relatively small molecule compounds, which are easily degraded in vivo and will not be damaged by accumulation in vivo. In addition, the small molecule polypeptide is easy to absorb, is not easy to be degraded by gastrointestinal protease, and can be orally taken.
BACKGROUND: Nearly three out of four older people will use the emergency department (ED) during their last year of life. However, most of them do not benefit from palliative care. Providing palliative care is a real challenge for ED clinicians who are trained in acute, life-saving medicine. Our aim is to understand the ED's role in providing palliative care for this population.
METHODS: We designed a qualitative study based on 1) interviews - conducted with older patients (≥ 75 years) with a palliative profile and their informal caregivers - and 2) focus groups - conducted with ED and primary care nurses and physicians. Palliative profiles were defined by the Supportive and Palliative Indicators tool (SPICT). Qualitative data was collected in French-speaking Belgium between July 2021 and July 2022. We used a constant inductive and comparative analysis.
RESULTS: Five older patients with a palliative profile, four informal caregivers, 55 primary and ED caregivers participated in this study. A priori, the participants did not perceive any role for the ED in palliative care. In fact, there is widespread discomfort with caring for older patients and providing palliative care. This is explained by multiple areas of tensions. Palliative care is an approach fraught with pitfalls, i.e.: knowledge and know-how gaps, their implementation depends on patients'(co)morbidity profile and professional values, experiences and type of practice. In ED, there are constant tensions between emergency and palliative care requirements, i.e.: performance, clockwork and needs for standardised procedures versus relational care, time and diversity of palliative care projects. However, even though the ED's role in palliative care is not recognised at first sight, we highlighted four roles assumed by ED caregivers: 1) Investigator, 2) Objectifier, 3) Palliative care provider, and 4) Decision-maker on the intensity of care. A common perception among participants was that ED caregivers can assist in the early identification of patients with a palliative profile.
CONCLUSIONS: Currently, there is widespread discomfort regarding ED caregivers caring for older patients and providing palliative care. Nonetheless, ED caregivers play four roles in palliative care for older patients. In the future, ED caregivers might also perform the role of early identifier.
In the controlled clinical trials, mild pain (including transient burning and stinging) was reported by about 30% of patients in both the active and placebo arms; treatment was discontinued in 2 of these patients. Local pruritus occurred in 4% of these patients. In all studies, there was no significant difference between the drug and placebo group in the rate or type of reported adverse reactions nor were there any differences in abnormal clinical laboratory findings.

Observed During Clinical Practice: Based on clinical practice experience in patients treated with acyclovir ointment in the U.S., spontaneously reported adverse events are uncommon. Data are insufficient to support an estimate of their incidence or to establish causation. These events may also occur as part of the underlying disease process. Voluntary reports of adverse events that have been received since market introduction include:

General: Edema and/or pain at the application site.

Skin: Pruritus, rash.

To report SUSPECTED ADVERSE REACTIONS, contact Solco Healthcare US, LLC at 1-866-257-2597 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Participants received atezolizumab (840 milligrams \[mg\]) via intravenous (IV) infusion every 2 weeks in combination with nab-paclitaxel (125 milligrams per square meter \[mg/m\^2\]) via IV infusion every week for 12 weeks, followed by atezolizumab (840 mg) every 2 weeks in combination with doxorubicin (60 mg/m\^2) and cyclophosphamide (600 mg/m\^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants continued to receive unblinded atezolizumab post-surgery at a fixed dose of 1200 mg by IV infusion every 3 weeks for 11 doses, for a total of approximately 12 months of atezolizumab therapy.
Self-administered subcutaneously once daily in the morning, at the same time.The initial dose for patients switching from insulin glargine is 80% of the total daily dose of basal insulin agent that was discontinued. Thereafter, insulin glargine (U300) will follow a titration algorithm for dose adjustment.
The present invention relates to a medicinal plaster for treating cervical vertebra diseases. Sesame oil is used for frying medicine to be dry; seasoning for preparing the medicinal plaster is used for preparing medicinal oil into the medicinal plaster. The medicinal plaster is composed of ginseng, milk vetch, sea horse, gecko, antler, donkey-hide gelatin, psoralea fruit, dipsacus root, dog bones, tortoise plastron, turtle shell, magnolia bark, mulberry twig, hemlock parsley, leech, pangolin, spina gleditsiae, earthworm, salvia miltiorrhiza, white mustard seed, zanthoxyli, cubeb, Chinese rose, frankincense, myrrh, scorpion, peach kernel, safflower, kudzuvine root, grassleaved sweetflag rhizome, musk, centipede, mistletoe, chrysanthemum, ligusticum, living balm cricket, red elder and pig coffin bone. The medicinal plaster of the present invention has the advantages of new components, dainty sorting, reasonable compatibility, pure Chinese medicinal components, small side effect, convenient operation and good and fast therapeutic effects. Proved by the use condition of a clinical patient, the present invention has fast and exact therapeutic effects; an effective rate achieves 98%, and a cure rate achieves 95% for curing cervical vertebra syndromes and neurasthenia. The medicinal plaster of the present invention has the advantages of moderate viscidity, firm application, no motion and good use performance.
The invention relates to a new method of preparation of a hyaluronan derivative with an aldehydic group in the position (6) of the polysaccharide glucosamine part. The hyaluronic acid oxidation can be performed by means of TEMPO/NaCIO or TEMPO/TCC systems in a protic environment with or without the presence of anorganic salts. Thus prepared aldehyde can be used for binding amines, diamines, amino acids, peptides and other compounds containing an amino group, e.g. by means of the reductive amination with NaBH 3 CN in water or in a water-organic solvent system. When a diamine or compounds containing three or more amino groups are used, cross-linked hyaluronan derivatives can be prepared. Cross-linked derivatives can be also prepared by a reaction of the aldehyde with a hyaluronan substituted by an amino-alkyl group HA-alkyl-NH 2 .
This paper presents interdisciplinary research exploring the development of inclusive multisensory science books, communicating immunology data for blind, low-vision and diverse-needs audiences. The research adopted an inductive theory-building approach, practice-based art methods and music and design methods, leveraging the lived experience of a legally blind artist. The research also involved designers and scientists in a cocreation process, producing books that incorporate tactile artworks, Braille-inspired protein models, image sonification and interaction. Two multisensory book titles, "The Heroes Within You: A Multisensory Exploration of Infection and Immunity" and "My Goodness: A Multisensory Exploration of Nutrition and Immunity", were developed for the Monash Sensory Science 2023 Exhibition Day. The books offer an innovative way to make science and art more accessible and engaging, addressing the limitations of traditional museum methods. Feedback from audiences has been positive, emphasizing the fascination, sensory engagement and ease of understanding. This paper highlights the potential for an interdisciplinary and inclusive approach to science and art, demonstrating the value of multisensory books as tools for science communication. The findings highlight the positive reception of this novel approach and suggest its potential for broader applications, promoting inclusivity and accessibility.
The antiseptic gel is made of 16-20 wt.% of poloxamer 407 basis. Additionally, 0.01-2.0 or 0.05-0.1 wt.% of octenidine or polihexanide as active substance, 58 wt.% of water, and glycerin are also provided. The gel has viscosity increase of 20 Pas in 18-25o?C temperature range within a range of 2o?C. An independent claim is also included for a method for production of an antiseptic gel, which involves carrying out the production of the gel under aseptic conditions. ACTIVITY : Vulnerary. MECHANISM OF ACTION : None given.
PURPOSE:To precisely and continuously fractionate a fat-soluble physiologically active substance at a high speed by subjecting the fat-soluble physiologically active substance to fractionating operation with an organic solvent converted into a poor solvent using a high-pressure gas and extracting operation with a supercritical fluid. CONSTITUTION:A high-pressure gas such as carbon dioxide is dissolved in a solution containing a fat-soluble physiologically active substance in a natural resource such as a plant in an organic solvent (e.g. ethanol), which is then converted into a poor solvent at 10-60 deg.C under 5-80kg/cm<2> pressure to separate the highly polar physiologically active substance as a crystal or a concentrated liquid. Furthermore, a supercritical fluid (e.g. gaseous carbon dioxide) is mixed with the solution thereof in the organic solvent after separating a highly polar physiologically active substance and the extracting operation with the supercritical fluid is carried out at 35-100 deg.C under 100-500kg/cm<2> pressure to separate the supercritical fluid phase containing a low polar physiologically active substance dissolved therein and the organic solvent phase containing a medium polar physiologically active substance dissolved therein. Thereby, the cost is remarkably reduced and the solution containing the fat-soluble physiologically active substance in the organic solvent is continuously fractionated.
At SOC clinics, patients will receive usual care for management of contact tracing, screening, and IPT provision. Childhood TB in Lesotho is managed by nurses in health centers. Per national guidelines, TB patients are asked to bring in child contacts, who are screened using a simple symptom questionnaire. Children who screen negative are assessed for IPT eligibility. Absent contra-indications (eg, active hepatitis, regular alcohol consumption, peripheral neuropathy), nurses counsel children and guardians on IPT benefits, potential side effects, and importance of adherence. Children requiring chest x-rays or gastric lavage and HIV-infected children under age 1 are referred to the hospital. After initiation, patients and guardians return to the clinic monthly for monitoring for side effects, TB symptoms, adherence, and 30-day supply of isoniazid. If adherence problems are noted, the nurse counsels patient and guardian as appropriate.
Patients in the gabapentin group will receive gabapentin preoperatively, one time dose of 10 mg/kg PO (maximum dose 600 mg) and will resume scheduled doses postoperatively of PO gabapentin, 300 mg PO every 8 hours, in addition to acetaminophen and ibuprofen for 7 days postoperative. Acetaminophen 15mg/kg PO (max 1 gm) every 4-6 hours as needed for pain, max dose 4 gm per day; Ibuprofen 4-10 mg/kg PO divided over 8 hours as needed for pain, max dose 40 mg/kg/day; gabapentin, 10 mg/kg standing every 8 hours (22).
Postoperative pain, nausea, vomiting (PNV) and hypoxia are common in relation to laparoscopic bariatric surgery. Sympatholytic drugs might decrease the need for intravenous or Inhalation anesthetics and opioids. In this study we wanted to analyze effects of esmolol on intraoperative anesthetic-analgesic requirements, postoperative analgesic requirements, postoperative pain, PNV and hypoxia.

Methods: Sixty patients have been included. Propofol, fentanyl and rocuronium were used for induction. Study groups were as follows; group E Esmolol infusion was added to maintenance anesthetics (Sevoflurane and fentanyl), group N only Sevoflurane and fentanyl was used during maintenance. They have been monitored during the intraoperative period and postoperatively for 24 h for analgesic requirements and PNV. Visual analog scale (VAS) scores for pain was also been assessed.
Two double‑blind, placebo‑controlled clinical trials were conducted in 1,856 healthy adults and adolescents (aged greater than or equal to 12 years) with a history of recurrent cold sores. Subjects self‑initiated therapy at the earliest symptoms and prior to any signs of a cold sore. The majority of subjects initiated treatment within 2 hours of onset of symptoms. Subjects were randomized to VALTREX 2 grams twice daily on Day 1 followed by placebo on Day 2, VALTREX 2 grams twice daily on Day 1 followed by 1 gram twice daily on Day 2, or placebo on Days 1 and 2.

The mean duration of cold sore episodes was about 1 day shorter in treated subjects as compared with placebo. The 2-day regimen did not offer additional benefit over the 1-day regimen.

No significant difference was observed between subjects receiving VALTREX or placebo in the prevention of progression of cold sore lesions beyond the papular stage.